Paper Details

  1. Home
  2. Paper Details

Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.

Author: CanterB, KaradenizC, OğuzA, SerdaroğluA

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the incidence rate of convulsions associated with imipenem/cilastatin in children with systemic malignancies. 3.6% of patients experienced seizures, suggesting a potential risk in this population.
Paper Details　
Original Abstract of the Article :
Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. Most studies report incidence rates ranging from 1.5 to 3%. There is no study on the incidence rate among children with systemic malignancies. Eighty-two patients with various malignancies who received imipenem/cila...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/08880010050122852

データ提供：米国国立医学図書館（NLM）

Imipenem/Cilastatin: A Double-Edged Sword in Pediatric Cancer

Imipenem/cilastatin is a powerful antibiotic commonly used to combat infections, but it can also cause seizures. This research investigates the incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.

Navigating the Risk of Seizures

The study found that 3.6% of pediatric cancer patients who received imipenem/cilastatin experienced seizures. This highlights the importance of careful monitoring for seizure activity in children receiving this antibiotic, especially those with pre-existing conditions that could increase their risk of seizures.

Balancing Antibiotic Benefits and Seizure Risk

This study emphasizes the need for a careful assessment of the risks and benefits of using imipenem/cilastatin in pediatric cancer patients. While the antibiotic can effectively combat infections, the potential for seizures requires close monitoring and a thoughtful approach to treatment.

Dr.Camel's Conclusion

This research provides valuable information regarding the incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin. The study's findings highlight the importance of careful monitoring for seizure activity in children receiving this antibiotic, particularly those with pre-existing conditions that could increase their risk. The knowledge gained from this study can help clinicians make informed decisions regarding the use of imipenem/cilastatin in pediatric cancer patients, balancing the benefits of antibiotic therapy with the potential risk of seizures.

Date :
  1. Date Completed 2001-03-15
  2. Date Revised 2019-10-25
Further Info :

Pubmed ID

11033734

DOI: Digital Object Identifier

10.1080/08880010050122852

Related Literature

Article Analysis
・Side Effects of imipenem
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.